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ABSTRACT
OBJECTIVE
To estimate all cause mortality and cause specific 
mortality among patients taking proton pump 
inhibitors (PPIs).
DESIGN
Longitudinal observational cohort study.
SETTING
US Department of Veterans Affairs.
PARTICIPANTS
New users of PPIs (n=157 625) or H2 blockers 
(n=56 842).
MAIN OUTCOME MEASURES
All cause mortality and cause specific mortality 
associated with taking PPIs (values reported as number 
of attributable deaths per 1000 patients taking PPIs).
RESULTS
There were 45.20 excess deaths (95% confidence 
interval 28.20 to 61.40) per 1000 patients taking 
PPIs. Circulatory system diseases (number of 
attributable deaths per 1000 patients taking PPIs 
17.47, 95% confidence interval 5.47 to 28.80), 
neoplasms (12.94, 1.24 to 24.28), infectious 
and parasitic diseases (4.20, 1.57 to 7.02), and 
genitourinary system diseases (6.25, 3.22 to 9.24) 
were associated with taking PPIs. There was a graded 
relation between cumulative duration of PPI exposure 
and the risk of all cause mortality and death due 
to circulatory system diseases, neoplasms, and 
genitourinary system diseases. Analyses of subcauses 
of death suggested that taking PPIs was associated 
with an excess mortality due to cardiovascular 
disease (15.48, 5.02 to 25.19) and chronic kidney 
disease (4.19, 1.56 to 6.58). Among patients without 
documented indication for acid suppression drugs 
(n=116 377), taking PPIs was associated with an 
excess mortality due to cardiovascular disease (22.91, 
11.89 to 33.57), chronic kidney disease (4.74, 1.53 to 
8.05), and upper gastrointestinal cancer (3.12, 0.91 to 
5.44). Formal interaction analyses suggested that the 
risk of death due to these subcauses was not modified 
by a history of cardiovascular disease, chronic kidney 
disease, or upper gastrointestinal cancer. Taking 
PPIs was not associated with an excess burden of 
transportation related mortality and death due to 
peptic ulcer disease (as negative outcome controls).
CONCLUSIONS
Taking PPIs is associated with a small excess of cause 
specific mortality including death due to cardiovascular 
disease, chronic kidney disease, and upper 
gastrointestinal cancer. The burden was also observed 
in patients without an indication for PPI use. Heightened 
vigilance in the use of PPI may be warranted.
Introduction
Proton pump inhibitors (PPIs) are widely used either as 
prescription or over-the-counter drugs.1 2 Several studies 
suggest that taking PPIs is associated with a number 
of serious adverse events including cardiovascular 
disease, acute kidney injury, chronic kidney disease, 
dementia, pneumonia, gastric cancer, Clostridium 
difficile infections, and osteoporotic fractures.3 Some of 
these adverse events are associated with an increased 
risk of death. Recent studies described an excess risk 
of all cause mortality among patients taking PPIs.4 
However, a detailed quantitative analysis of the cause 
specific mortality that is attributable to taking PPIs 
is not available. We hypothesized that taking PPIs is 
associated with an increased risk of cause specific 
mortality that are mapped to well characterized adverse 
events of PPIs. Identification of specific causes of death 
attributable to taking PPIs will inform the public about 
the risk of taking PPIs in the long term and could inform 
risk stratification, risk mitigation strategies, and help 
shape the development of deprescription interventions 
to reduce unnecessary or un-indicated PPI use. In this 
work, we built a longitudinal cohort of 214 467 United 
States veterans that were new users of acid suppression 
drugs— histamine H2 receptor antagonists (H2 blockers) 
or PPIs—and developed analytic strategies to estimate 
the all cause mortality and cause specific mortality 
associated with taking PPIs.
Methods
Overall study design and specification of a target 
trial
We designed the cohort, exposure definitions, 
covariate choices, outcome definitions, and an 
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analytic strategy based on the framework proposed by 
Hernán and Robins.5 We emulated a target randomized 
controlled trial of the comparative effect of new use of 
PPIs versus H2 blockers on the risk of all cause and 
cause specific mortality (details of the specified target 
trial protocol are presented in supplemental table 
1). We then employed causal inference strategies to 
estimate the mortality attributable to PPI use (further 
described in the methods and in supplemental 
table 1).
Cohort design
We selected new users of acid suppression drugs 
between 1 July 2002 and 30 June 2004 and followed 
them for up to 10 years to examine the associations 
between new use of PPIs and causes of death. New use 
was defined as having no record of an acid suppression 
drug prescription between 1 October 1999 and 30 June 
2002.
There were 405 490 new users of PPIs. To reduce the 
probability of misclassification, we further selected 
from this cohort 201 557 patients who were prescribed 
more than a 90 day supply of a PPI in the 180 day 
period after new PPI use. Additionally, 24 061 patients 
were excluded because they were taking H2 blockers 
during the 180 day period, resulting in 177 496 new 
users of PPI.
There were 212 735 new users of H2 blockers and 
69 731 of them were prescribed more than a 90 day 
supply in the 180 day period after new H2 blocker use. 
In this group of patients, 9528 were excluded because 
they were taking PPIs during the 180 day period, 
resulting in 60 203 new users of H2 blockers.
In the two groups of new users of acid suppression 
drugs, 234 950 patients had known sex, race, and 
date of birth and were alive after 180 days of their 
first record of prescription. We selected new users 
whose prescribing physician had also prescribed PPIs 
or H2 blockers to other new users within the one year 
before the cohort patient’s first acid suppressant drug 
prescription, to facilitate building an instrumental 
variable. We further selected new users whose 
prescribing facility and clinic are known, yielding a 
final cohort of 214 467 patients (fig 1).
Data sources
We used Department of Veterans Affairs databases in 
the study.6 The Department of Veterans Affairs operates 
the largest integrated healthcare system in the US—a 
veteran specific national health service—to discharged 
veterans of the US armed forces.7 The Department of 
Veterans Affairs provides a broad range of healthcare at 
1400 healthcare facilities, including 143 Department 
of Veterans Affairs hospitals and 1241 outpatient sites 
of care of varying complexity to over 9 million veterans 
(estimated in 2018) enrolled in the Department of 
Veterans Affairs healthcare program.7-9 All enrolled 
veterans have access to the Department of Veterans 
Affairs’s comprehensive medical benefits package 
including inpatient hospital care; outpatient services; 
preventive, primary, and specialty care; prescriptions; 
mental healthcare; home healthcare; geriatric and 
extended care; medical equipment; and prosthetics.8 9
We used medical SAS datasets from the 
Department of Veterans Affairs corporate data 
warehouse, which provided data on inpatient and 
outpatient encounters, to obtain information about 
demographic characteristics, healthcare system 
and clinic encounters, comorbidities, procedures, 
and surgeries.10-17 We also collected demographic 
information from the Department of Veterans Affairs 
Vital Status databases.6 The Department of Veterans 
Affairs Managerial Cost Accounting System Laboratory 
Results from Department of Veterans Affairs corporate 
data warehouse provided laboratory results of cohort 
patients.10-14 17-20 The Department of Veterans Affairs 
corporate data warehouse Outpatient Pharmacy 
domain provided outpatient prescription records and 
an identifier for the hospital and Veterans Integrated 
Service Network in which the prescription was 
provided.4 21-23 Additionally, we used National Death 
Index data to collect information about date of death 
and the underlying cause of death.24
Outcomes
Study outcomes were specific causes of death based 
on national death index underlying cause of death 
coded based on ICD-10 (international classification 
of diseases, 10th revision).24 25 Causes of death were 
categorized into the following categories: circulatory 
system diseases; neoplasms; respiratory system 
diseases; external causes; endocrine, nutritional, 
and metabolism diseases; nervous system diseases; 
digestive system diseases; mental and behavioral 
disorders; genitourinary system diseases; infectious 
and parasitic diseases; and other causes. Based on 
results from causes of death, we further defined 
subcauses of death within those categories which 
exhibited statistical significance and for which there 
existed well characterized evidence supporting a 
relation between taking PPIs and adverse events which 
could be associated with cause specific mortality.3 
These subcauses included death due to cardiovascular 
diseases, upper gastrointestinal cancer, Clostridium 
difficile infections, and chronic kidney disease.3
Exposure
We applied an intention to treat design for new use of 
acid suppressant drugs. Intention to treat with PPIs was 
defined as a prescription of more than a 90 day supply 
of a PPI in the 180 day period since first prescription, 
and with no H2 blocker prescriptions within this 
period. Intention to treat with H2 blockers, which 
served as an active comparator control, was defined as 
a prescription of more than a 90 day supply of an H2 
blocker in the 180 day period since first prescription, 
and with no PPI prescriptions within this period. Use 
of an active comparator, compared with a non-user 
control, allows for comparison to those who were 
prescribed another drug with similar indications; this 
approach might increase the overlap of characteristics 
between groups, and might reduce the potential for 
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confounding by indication.26 In all analyses, we used 
days of supply as an indication of number days with a 
prescription.
Covariates
We collected covariates within one year before the 
first acid suppressant prescription. We selected 
basic demographics, health service utilization 
characteristics, and indications for prescription of 
acid suppressant drugs based on previous knowledge 
including age, sex, race, year of first prescription, 
number of outpatient visits, total length of stay 
in hospital, level of complexity of the hospital in 
which the prescription was provided, type of clinic 
in which the prescription was provided, location of 
the hospital where the prescription was provided, 
gastresophageal reflux disease, upper gastrointestinal 
tract bleeding, ulcer disease, H pylori infection, 
Barrett’s esophagus, achalasia, stricture, and 
esophageal adenocarcinoma.4 16 17 27 28 Age, number of 
outpatient visits and total length of stay hospital were 
modeled as cubic spline functions. Level of hospital 
complexity was defined as outpatient clinic, medical 
center, and healthcare system. Clinic type was defined 
as gastroenterology, primary care, and other. Location 
of hospital was defined by the Veterans Integrated 
Service Network.29 30 To more closely emulate our 
target trial, which would have random assignment 
of acid suppressant drug, and to reduce bias from 
non-random assignment by reducing imbalances in 
patient characteristics between PPIs and H2 blockers, 
we built a high dimensional propensity score using 
pre-exposure information in domains including 
outpatient ICD-9 (international classification of 
diseases, ninth revision) diagnoses, outpatient Current 
Procedural Terminology codes, inpatient ICD-9 
diagnoses, inpatient procedures, inpatient surgeries, 
and outpatient pharmacy and laboratory records.31 
We used physicians’ prescribing preference as an 
instrumental variable to reduce the probability that 
an observed association (between PPIs and causes of 
death) is contributed by unmeasured confounders.32 33
Statistical analyses
Characteristics and outcome events of cohort patients 
for the PPI and H2 blocker groups are reported as 
number and percentage, mean and standard deviation, 
or median and interquartile range, as appropriate. 
Kaplan-Meier curves of all cause mortality in new users 
of PPIs and H2 blockers are presented.
To more closely mimic a target trial where new use 
of PPIs and H2 blockers is randomly assigned, we 
used the approach developed by Schneeweiss and 
colleagues to generate high dimensional propensity 
scores. This approach selects potential confounders 
among those included in our data domains based 
on their relative association for new use of PPIs 
compared with new use of H2 blockers.31 34 We then 
used predefined covariables and algorithmically 
selected covariates together to generate propensity 
scores.35 36 We applied inverse treatment probability 
weights based on the propensity scores to the cohort, 
which results in a weighted pseudo cohort where 
treatment assignment is independent of measured 
confounders.37 For the PPIs and H2 blockers groups, 
plots of the distributions of the propensity scores and 
standardized differences before and after weighting 
are provided in supplemental figures 1a-c.
To reduce bias from unmeasured confounding, we 
applied instrumental variable analyses using the two-
stage residual inclusion method to the weighted pseudo 
cohort.32 33 38 We used physician-specific prescribing 
No PPI use within 180 day period
>90 day supply of H
2
 blocker in 180 day period
New users of acid suppression drugs
First prescription between 1 July 2002 and 30 June 2004










 blocker use within 180 day period
177 496
>90 day supply of PPI in 180 day period
201 557
618 225
With known sex, race, and date of birth, and alive aer 180 days of first prescription
234 950
With known prescribing physician and facility data
214 467
Fig 1 | Flowchart for cohort building
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preference as the instrumental variable to account for 
unmeasured confounders that might not be accounted 
for in the high dimensional propensity score, which 
could include severity of diseases and other treatment 
indications.39 In the first stage, the residual between 
the observed and predicted probability of receiving 
the assigned treatment given instrumental variable 
was computed from logistic regression weighted by 
inverse treatment probability weights based on high 
dimensional propensity scores. In the second stage, 
we used the residual as an independent variable 
indicating unmeasured confounders in the inverse 
treatment probability weighted cause specific Cox 
survival analyses and Fine and Gray survival analyses. 
Physician prescription preferences in past patients 
has been used as an instrumental variable in the 
conduction of pharmacoepidemiologic studies.39 40 41 
To assess the strength of our instrumental variable, 
we conducted a logistic regression of the odds of being 
prescribed PPIs versus H2 blockers. Results suggested 
that a 10% increase in a physician prescribing 
preference toward prescribing PPIs in past patients 
was associated with a 35% (95% confidence interval 
35% to 35%) increase in odds of the current patient 
being prescribed PPIs compared with H2 blockers after 
adjustment for patient characteristics at the time of 
prescription. These results suggest that we do not have 
a weak instrumental variable. Further discussion on 
instrumental variable assumptions can be found in the 
supplemental methods.
We also applied negative and positive controls to 
examine if potential biases could have modified the 
relation between PPI use and cause specific mortality. 
We examined acute kidney injury as a positive outcome 
control, where previous studies have shown a relation 
with PPIs.22 We examined transportation related death 
as a negative outcome control following the approach 
described by Lipsitch and colleagues, where—based on 
current knowledge—we assumed that there should be 
no causal relation between PPI use and transportation 
related mortality.42 The relation of this exposure-
outcome pair could share the same potential biases 
with PPIs and other cause specific deaths including 
unmeasured confounders, modeling algorithms, 
exposure measurement, outcome ascertainments, and 
other biases.42 We also applied death due to peptic ulcer 
disease as an additional negative outcome control, 
where, based on previous knowledge, we expect that 
PPI users should not have a higher risk of death due to 
peptic ulcer disease if treatment by indication has been 
accounted for; the choice of this outcome control was 
motivated by the fact that peptic ulcer disease is an 
underlying indication for PPI use and that the relation 
between this exposure-outcome pair could have the 
same potential bias as PPIs and other outcomes in the 
field of treatment by indication.43
In addition to the intention to treat design, since a 
proportion of new users of H2 blockers used PPIs later 
during follow-up, we conducted a sensitivity analyses 
that examined PPI ever-use as a time varying exposure. 
We also conducted a duration analysis in new users 
of PPIs where cumulative exposure was defined as 
the total number of days of PPI supply up to the last 
day of prescription. To address immortal time bias, 
the T0 in this analysis was set to be the end of the last 
prescription.4
To further evaluate cause specific mortality, we 
analyzed detailed subcauses of death (as detailed 
in the outcomes section). In addition, to remove 
potential confounding by gastrointestinal disease 
severity, we repeated the analyses in a sub cohort 
where patients had no documented gastrointestinal 
indications for acid suppression drugs before receipt of 
the first prescription. Moreover, we conducted formal 
interaction analyses to examine whether the presence 
of a baseline comorbid condition modified the relation 
between new PPI use and its related cause specific 
mortality.
Main results are reported as the event rate per 100 
people in the PPIs and H2 blockers groups, and as 
estimated excess burden associated with new use 
PPI per 1000 people based on estimated cumulative 
incidence rate probability at 10 years. To account 
for the impact on variance that results from inverse 
probability of treatment weighting and two stage 
residual inclusion methods,33 44 we analyzed 1000 
bootstrapped samples, and report the 2.5 and 97.5 
centiles as 95% confidence intervals.
A 95% confidence interval that does not cross 0 
for absolute risk and does not cross 1 for ratio was 
considered statistically significant. Figure 2 and the 
supplemental methods show a detailed description of 
the analytic approach. All analyses were done using 
SAS Enterprise Guide version 7.1 (SAS Institute, Cary, 
NC). The study was approved by the Institutional 
Review Board of the Department of Veterans Affairs St 
Louis Health Care System, St Louis, MO.
Patient and public involvement
No patients were involved in developing the hypothesis, 
the specific aims, or the research questions, nor 
were they involved in developing plans for design or 
implementation of the study. No patients were involved 
in the interpretation or writing up of results. There are 
no plans to disseminate the results of the research to 
study participants.
Results
Table 1 shows the demographic and health chara-
cteristics of the overall cohort of new users of acid 
suppression drugs (n=214 467), by the type of acid 
suppressant drug at the time of cohort entry (PPIs, 
n=157 625; H2 blockers, n=56 842). In the overall 
cohort, the average age was 65.10 (±12.25), 95.93% 
were male, and 87.43% were white. Table 2 and 
supplemental table 2 show that among new users of 
PPIs, rabeprazole 20 mg once a day, omeprazole 20 
mg once a day, and rabeprazole 20 mg twice a day 
accounted for 58.78%, 21.66%, and 8.41% of all 
initial PPI prescriptions, respectively. Over a median 
duration of follow up of 10 years (interquartile range 
6.95-10.00), there were 80 062 (37.33%) deaths. 
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The most common causes of death were circulatory 
system diseases (12.45%), neoplasms (9.72%), 
and respiratory system diseases (4.80%). There 
were more deaths among patients taking PPIs than 
those taking H2 blockers (37.92% and 35.69%, 
respectively). Table 1 shows that the median time-to-
death was 4.84 (interquartile range 2.35-7.38) and 
4.96 (2.49-7.48) years in the PPIs and H2 blockers 
groups, respectively. Kaplan-Meier curves for the PPIs 
and H2 blockers new use groups are presented in 
supplemental figure 2.
Development of a target trial and application of 
positive and negative controls
To estimate the association between exposure to PPIs 
and causes of death, we aimed to emulate a target 
trial where patients would be randomly assigned to 
new use of PPIs or H2 blockers for more than 90 days 
(supplemental table 1). We followed the approach 
outlined by Hernán and Robins of using big data to 
emulate a target trial when a randomized trial is not 
available5; we designed a multipronged approach 
involving several strategies detailed in supplemental 
table 1. To further resolve concerns about spurious 
associations, we first applied a positive control to 
examine the association between exposure to PPIs 
and the risk of acute kidney injury where a priori 
knowledge suggests an association is expected.3 4 21 22 
Table 3 shows that the results suggested that exposure 
to PPIs was associated with an increased burden of 
acute kidney injury (number of attributable cases per 
1000 PPI users 15.03, 95% confidence interval 1.17 to 
29.85). We then tested two negative controls following 
the approach outlined by Lipsitch and colleagues.42 
We first examined the association between PPI use and 
transportation related death where the relation of this 
exposure-outcome pair could share the same potential 
biases with PPIs and other cause specific deaths. Table 
Outpatient data sources
Diagnosis Procedure Laboratory Pharmacy
Inpatient data sources
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Fig 2 | Flowchart for analytic approach
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Characteristic Overall PPIs H2 blockers
Total 21 4467 157 625 (73.50) 56 842 (26.50)
Mean (SD) age (years) 65.10 (12.25) 65.51 (12.14) 63.97 (12.46)
Sex:
 Men 20 5748 (95.93) 151 399 (96.05) 54 349 (95.61)
 Women 8719 (4.07) 6226 (3.95) 2493 (4.39)
Race:
 White 187 519 (87.43) 138 967 (88.16) 48 552 (85.42)
 Black 20 089 (9.37) 14 193 (9.00) 5896 (10.37)
 Other 6859 (3.20) 4465 (2.83) 2394 (4.21)
Admitted to hospital in past year 20 794 (9.70) 15 221 (9.66) 5573 (9.80)
Median (IQR) length of stay among inpatients (days) 7 (4 to 13) 7 (4 to 13) 7 (4 to 14)
Median (IQR) no of outpatient visits 4 (1 to 10) 4 (1 to 10) 5 (2 to 11)
Disease:
 Diabetes mellitus 48 869 (22.79) 35 777 (22.70) 13 092 (23.03)
 Hypertension 116 536 (54.34) 85 136 (54.01) 31 400 (55.24)
 Chronic lung disease 29 517 (13.76) 21 588 (13.70) 7929 (13.95)
 Peripheral artery disease 2475 (1.15) 1745 (1.11) 720 (1.28)
 Cardiovascular disease 54 122 (25.24) 40 641 (25.78) 13 481 (23.72)
 Dementia 4747 (2.21) 3420 (2.17) 1327 (2.33)
 Hyperlipidemia 90 812 (42.34) 66 613 (42.26) 24 199 (42.57)
 Hepatitis C 1953 (0.91) 1403 (0.89) 550 (0.97)
 HIV 57 (0.03) 37 (0.02) 20 (0.04)
 Cancer 9738 (4.54) 7465 (4.74) 2273 (4.00)
Any documented gastrointestinal indication for acid suppression 
drugs
98 090 (45.74) 76 581 (48.58) 21 509 (37.84)
Gastresophageal reflux disease 83 904 (39.12) 64 602 (40.98) 19 302 (33.96)
Upper gastrointestinal tract bleeding 3356 (1.56) 3072 (1.95) 284 (0.50)
Ulcer disease 13 856 (6.46) 11 585 (7.35) 2271 (4.00)
H pylori infection 809 (0.38) 746 (0.47) 63 (0.11)
Barrett’s esophagus 597 (0.28) 588 (0.37) 9 (0.02)
Achalasia 66 (0.03) 60 (0.04) 6 (0.01)
Stricture 1288 (0.60) 1202 (0.76) 86 (0.15)
Esophageal adenocarcinoma 42 (0.02) 36 (0.02) 6 (0.01)
Drugs:
 Angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers
84 832 (39.34) 62 306 (39.53) 22 076 (38.84)
 Statins 86 546 (40.35) 64 440 (40.88) 22 106 (38.89)
 Nonsteroidal anti-inflammatory drugs 56 346 (26.27) 38 945 (24.71) 17 401 (30.61)
Mean (SD) estimated glomerular filtration rate (mL/min/1.73m2) 73.43 (21.03) 72.88 (21.14) 74.84 (20.69)
Median (IQR) HbA1C (%) 6.2 (5.6-7.3) 6.2 (5.6-7.2) 6.2 (5.6-7.3)
Mean (SD) systolic blood pressure (mmHg) 137.19 (19.64) 137.09 (19.64) 137.49 (19.63)
Mean (SD) diastolic blood pressure (mmHg) 76.17 (11.79) 75.97 (11.80) 76.74 (11.76)
Median (IQR) high density lipoprotein (mg/dL) 41.87(35.00-50.00) 41.60 (35.00-50.00) 42.00 (35.00-50.00)
Median (IQR) low density lipoprotein (mg/dL) 107.0 (86.0-131.4) 106.3 (85.0-131.0) 109.6 (88.0-133.0)
Smoking status:
 Current 41 809 (19.49) 28 928 (18.35) 12 881 (22.66)
 Former 44 216 (20.62) 34 247 (21.73) 9969 (17.54)
 Never 128 442 (59.89) 94 450 (59.92) 33 992 (59.80)
Median (IQR) washout period (days) 728 (174-1584) 675 (158-1565) 889 (230-1631)
Median (IQR) years of follow-up 10.00 (6.59-10.00) 10.00 (6.45-10.00) 10.00 (6.95-10.00)
Median (IQR) days of PPI prescription during follow-up 1278 (354-2591) 1682 (682-2879) 123 (0-1288)
Median (IQR) days of H2 blocker prescription during follow-up 0 (0-270) 0 (0-0) 597 (270-1299)
Median (IQR) time-to-death (years) 4.87 (2.39-7.40) 4.84 (2.35-7.38) 4.96 (2.49-7.48)
All cause mortality 80 062 (37.33) 59 776 (37.92) 20 286 (35.69)
Cause specific mortality:
 Circulatory system diseases 26 711 (12.45) 19 923 (12.64) 6788 (11.94)
 Neoplasms 20 847 (9.72) 15 529 (9.85) 5318 (9.36)
 Respiratory system diseases 10 294 (4.80) 7593 (4.82) 2701 (4.75)
 External causes 3406 (1.59) 2483 (1.58) 923 (1.62)
 Endocrine, nutritional, and metabolism diseases 3581 (1.67) 2628 (1.67) 953 (1.68)
 Nervous system diseases 3391 (1.58) 2574 (1.63) 817 (1.44)
 Digestive system diseases 3299 (1.54) 2552 (1.62) 747 (1.31)
 Mental and behavioral disorders 2114 (0.99) 1664 (1.06) 450 (0.79)
 Genitourinary system diseases 2373 (1.11) 1827 (1.16) 546 (0.96)
 Infectious and parasitic diseases 2114 (0.99) 1664 (1.06) 450 (0.79)
 Symptoms, signs, and abnormal clinical or laboratory results 789 (0.37) 588 (0.37) 201 (0.35)
Table 1 | Demographic and health characteristics of overall cohort and by type of acid suppressant drug. Values are 
numbers (percentages) unless stated otherwise
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3 shows that PPI exposure was not associated with 
excess burden of transportation related death (−0.21, 
−2.96 to 2.48). To verify that indication bias was 
accounted for, we then estimated the mortality due to 
peptic ulcer disease—an underlying indication for PPI 
use—as an additional negative outcome control where 
the relation between this exposure-outcome pair might 
share the same potential biases as PPIs and outcomes 
in the area of treatment by indication; the results 
showed no excess of peptic ulcer disease related death 
(−0.46, −2.43 to 0.27) suggesting that indication bias 
might have been accounted for.
Causes of death among patients taking PPIs
We then used our analytic approach to estimate the 
excess cause specific mortality burden associated with 
new use of PPIs. Details of the model construction 
are presented in figure 2 and supplemental table 1. 
Our results suggest that over the course of 10 years of 
follow-up there were 45.52 (95% confidence interval 
28.20 to 61.40) excess deaths per 1000 PPI users. 
Table 4 shows that over the follow-up period of 10 
years, causes of death which exhibited significant 
excess mortality associated with PPI use included 
circulatory system diseases (number of attributable 
deaths per 1000 PPI users 17.47, 95% confidence 
interval 5.47 to 28.80), neoplasms (12.94, 1.24 to 
24.28), genitourinary system diseases (6.25, 3.22 to 
9.24), and infectious and parasitic diseases (4.20, 1.57 
to 7.02). Notably, taking PPIs was not associated with 
increased mortality due to digestive system diseases 
(0.43, −3.72 to 4.07). The results were consistent in 
sensitivity analyses where exposure was treated as 
time varying (supplemental table 3).
Table 5 shows that in analyses evaluating the 
relation between cumulative duration of exposure and 
the risks of all cause and cause specific mortality, there 
was a graded relation between duration of exposure 
and risks of all cause mortality, death due to circulatory 
system diseases, neoplasms, and genitourinary 
system diseases. The risk of death due to infectious 
and parasitic diseases was not related to duration of 
exposure.
Subcauses of death
Because our results showed excess deaths due to 
circulatory system diseases, neoplasms, genitourinary 
system diseases, and infectious and parasitic diseases, 
we further examined excess death in subcauses of 
these conditions which could be mapped to adverse 
events of PPIs, which are well characterized. These 
subcauses included death due cardiovascular diseases, 
upper gastrointestinal cancer, Clostridium difficile 
infections, and chronic kidney disease.3 Table 6 shows 
that we observed excess deaths due to cardiovascular 
disease (number of attributable deaths per 1000 PPI 
users 15.48, 95% confidence interval 5.02 to 25.19) 
and chronic kidney disease (4.19, 1.56 to 6.58), but 
not due to upper gastrointestinal cancer (1.72, −0.15 
to 3.74) or Clostridium difficile infections (0.65, −0.18 
to 1.70). 
We examined the association between PPI use and 
the four subcauses in patients without documented 
gastrointestinal indication for acid suppression drugs. 
Table 7 shows that there is an excess of cause specific 
mortality associated with taking PPIs for cardiovascular 
diseases (number of attributable deaths per 1000 PPI 
users 22.91, 95% confidence interval 11.89 to 33.57), 
upper gastrointestinal cancer (3.12, 0.91 to 5.44), and 
chronic kidney disease (4.74, 1.53 to 8.05).
Formal interaction analyses were undertaken 
to evaluate whether the presence of baseline 
cardiovascular disease, upper gastrointestinal cancer, 
or chronic kidney disease modified the association 
between PPI use and the related subcauses of death. 
Results suggest no significant interaction for death due 
to cardiovascular diseases (P=0.22 for interaction), 
upper gastrointestinal cancer (P=0.54 for interaction), 
and chronic kidney disease (P=0.10 for interaction). 
Interaction analyses between PPI use and history of 
Clostridium difficile infections could not be conducted 
because no patients in the H2 blockers group with 
Table 2 | Top three proton pump inhibitor (PPI) and H2 blocker prescriptions
Rank
PPIs H2 blockers
Prescription N (%) Prescription N (%)
1 Rabeprazole 20 mg once a day 92 650 (58.78) Ranitidine 150 mg twice a day 42 349 (74.50)
2 Omeprazole 20 mg once a day 34 149 (21.66) Ranitidine 150 mg once a day 82 25 (14.47)
3 Rabeprazole 20 mg twice a day 13 250 (8.41) Ranitidine 300 mg twice a day 3156 (5.55)
Table 1 | Continued
Characteristic Overall PPIs H2 blockers
 Musculoskeletal system diseases 342 (0.16) 267 (0.17) 75 (0.13)
 Blood diseases 287 (0.13) 223 (0.14) 64 (0.11)
 Skin and subcutaneous diseases 113 (0.05) 75 (0.05) 38 (0.07)
 Congenital malformations 44 (0.02) 33 (0.02) 11 (0.02)
 Ear and mastoid diseases 4 (0.00) 3 (0.00) 1 (0.00)
 Eye diseases 2 (0.00) 2 (0.00) 0 (0.00)
 Nonspecific* 21 (0.01) 18 (0.01) 3 (0.01)
PPIs=proton pump inhibitors; IQR=interquartile range
*Underlying cause of death missing
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history of Clostridium difficile infections experienced 
death due to Clostridium difficile.
Discussion
We examined the causes of death associated with new 
use of PPIs in a longitudinal observational cohort of US 
veterans. Overall, there were 45.20 attributable deaths 
per 1000 PPI users; 38.65% were related to circulatory 
system diseases, 28.63% to neoplasms,13.83% to 
genitourinary system diseases, and 9.29% to infectious 
and parasitic diseases. Analyses by subcauses of death 
suggest that new use of PPIs is associated with an 
excess of mortality from cardiovascular disease and 
chronic kidney disease; this pattern was consistent 
in analyses considering those without documented 
indication for acid suppression drugs. Increased risk 
of death due to upper gastrointestinal cancer was 
more evident in those without documented indication 
for acid suppression drugs. The risk of cause specific 
mortality was not modified by the presence of previous 
history of cardiovascular disease, chronic kidney 
disease, or upper gastrointestinal cancer.
Contextual evaluation of findings
PPIs are often used without indication and for 
much longer than needed.45-52 Evidence from the 
past several years suggests that taking PPIs is 
associated with serious adverse events including 
cardiovascular disease, pneumonia, osteoporotic 
fractures, Clostridium difficile infections, acute kidney 
injury, chronic kidney disease, dementia, and upper 
gastrointestinal cancer.3 We previously described an 
excess risk of all cause mortality among PPI users.4 
In this report, we used advanced causal inference 
methods to identify and estimate the excess of cause 
specific mortality associated with taking PPIs. Our 
findings suggest that although PPI use might be 
associated with many serious adverse events, excess 
mortality was only mapped to a few specific causes 
including cardiovascular disease, chronic kidney 
disease, and upper gastrointestinal cancer. Notably, 
excess burden was present in those without underlying 
documented indications for PPI use, that is, patients 
who may not benefit from PPI exposure. Our results, 
however, should not preclude prescription and use 
Table 3 | Positive and negative outcome controls
Outcome
Event rate per 100 (95% CI) Excess burden per 1000 
(95% CI)
Hazard ratio (95% CI)
PPIs H2 blockers Fine and Gray Cox


































*Positive outcome control. First acute kidney injury during follow up defined by ICD-9 584.
†Negative outcome control. Defined by ICD-10 V00-V99.
‡Negative outcome control. Defined by ICD-10 K20, K211, K226, K250-K289
Table 4 | Causes of death associated with proton pump inhibitor (PPI) use during 10 years of follow-up
Cause of death
ICD-10 cause of 
death
Event rate per 100 (95% CI) Excess burden per 
1000 (95% CI)
Hazard ratio (95% CI)
PPIs H2 blockers Fine and Gray Cox
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*Death from symptoms, signs, and abnormal clinical or laboratory result; musculoskeletal system diseases; blood diseases; skin and subcutaneous 
diseases; congenital malformations; ear and mastoid diseases; eye diseases; and nonspecific death
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of PPIs where medically indicated; nevertheless, the 
findings emphasize the need to promote awareness of 
potential adverse events of long term PPI use, for better 
pharmacovigilance, and the need to limit prescription 
of PPIs to patients where the benefits outweigh potential 
risks.1 Identification of those at high risk of adverse 
events attributable to taking PPIs is an important 
knowledge gap and could inform risk stratification and 
risk mitigation strategies. Future research should also 
investigate the best way to implement deprescription 
programs to reduce the unnecessary or un-indicated 
use of PPIs.51 53
We designed this study to evaluate the research 
question using a cohort from a time when the 
prevalence of PPI prescriptions was lower; and the 
doses prescribed were lower. Over 80% of new users of 
PPIs in our cohort had an initial dose that is equivalent 
to over-the-counter doses (table 2). That and the 
findings of increased risk of cause specific mortality 
with prolonged duration of exposure suggests 
that prescription PPI use should be limited to well 
documented indications (where patients may derive 
benefit), and for a well defined duration—defined by 
the underlying indication. Over-the-counter use of PPIs 
should only be for a brief duration of time (generally 
not to exceed 14 days).54 Efforts to target and reduce 
prolonged use of prescription PPIs without indications 
and to curtail extended use of over-the-counter PPIs 
might be a good approach.
Evidence suggests that taking PPIs is associated 
with an increased risk of cardiovascular disease and 
chronic kidney disease1 21 22; the finding in our study 
that taking PPIs is associated with an excess mortality 
due to cardiovascular disease and chronic kidney 
disease suggests that beyond the occurrence of the 
adverse events, excess PPI use is linked to loss of life. 
Furthermore, the results of formal interaction analyses 
show that the relation between taking PPIs and cause 
specific mortality (death due cardiovascular disease and 
chronic kidney disease) is not modified by the presence 
of related baseline comorbid condition, suggesting 
that the presence of baseline cardiovascular disease 
or chronic kidney disease does not increase the risk of 
PPI related cause specific mortality. The pathways in 
which exposure to PPIs leads to excess cause specific 
mortality is likely mediated by either worsening of the 
underlying baseline disease (cardiovascular disease or 
chronic kidney disease) or the occurrence of de novo 
disease (cardiovascular disease or chronic kidney 
disease) which would then heighten the risk of cause 
specific mortality. Experimental evidence from Yepuri 
and colleagues suggested a “unifying mechanism” 
for the association of PPI use with an increased 
risk of cardiovascular and kidney morbidity and 
mortality.55 The investigators reported that long term 
exposure to PPIs blunted lysosomal acidification and 
proteostasis in endothelial cells, increased oxidative 
stress, impaired endothelial function, and accelerated 
human endothelial senescence by reducing telomere 
length.55 Our findings of excess mortality due to 
cardiovascular disease and chronic kidney disease are 
consistent with this proposed biologic mechanism, 
Table 5 | Causes of death associated with cumulative exposure to proton pump inhibitors (PPIs) during 10 years of 






Infectious and  
parasitic diseases§
0-120 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
121-240 1.23 (1.12 to 1.34) 1.13 (0.97 to 1.31) 1.09 (0.93 to 1.29) 1.03 (0.62 to 1.71) 0.90 (0.57 to 1.43)
241-360 1.47 (1.34 to 1.60) 1.34 (1.15 to 1.55) 1.19 (1.01 to 1.39) 1.20 (0.72 to 1.99) 0.94 (0.59 to 1.49)
361-480 1.63 (1.49 to 1.79) 1.37 (1.17 to 1.59) 1.25 (1.06 to 1.48) 1.30 (0.77 to 2.18) 0.96 (0.60 to 1.55)
481-600 1.71 (1.56 to 1.87) 1.46 (1.25 to 1.70) 1.25 (1.06 to 1.48) 1.48 (0.88 to 2.48) 0.90 (0.56 to 1.45)
P value for trend <0.001 <0.001 0.002 0.005 0.93





Table 6 | Subcauses of death associated with proton pump inhibitor (PPI) use during 10 years of follow-up
Cause of death Subcause of death
Event rate per 100 (95% CI) Excess burden 
per 1000  
(95% CI)
Hazard ratio (95%CI)
PPIs H2 blockers Fine and Gray Cox
Circulatory system 
diseases
















































Subcauses are subcategories of causes of death which exhibited significant association with PPI use and for which there was well characterized evidence 
supporting a relation between taking PPIs and adverse events which may be associated with cause specific mortality.
*ICD10 I21-I24.0, I24.2-I25.2, I25.8-I25.9, I60-I69
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but do not exclude the possible contributions of other 
mechanisms including those mediated by activation of 
the heme oxygenase-1 enzyme in endothelial cells and 
microbiome perturbation.56-58
Analyses by subcauses within the death due to 
neoplasm category suggested that mortality due to 
upper gastrointestinal cancer was more evident in 
those without gastrointestinal indication for use of 
acid suppression drugs, likely a manifestation of 
lower baseline risk. The findings are consistent with 
emerging evidence suggesting that long term exposure 
to PPIs increases the risk of gastric malignancy.59-67 A 
recent study by Cheung and colleagues examined the 
risk of gastric cancer in a cohort of 63 397 patients 
and reported excess burden among long term users 
of PPI.66 The investigators reported that the adjusted 
absolute risk difference for PPI use versus non-PPI use 
for excess gastric cancer was 4.29 (95% confidence 
interval 1.25 to 9.54) per 10 000 person years.66 
Wan and colleagues conducted a meta-analysis of 
926 386 patients and found that long term PPI use 
was associated with a twofold risk of gastric cancer 
(odds ratio 2.10, 95% confidence interval 1.10 to 
3.09).64 The underlying mechanism(s) by which long 
term exposure to PPIs might increase the risk of gastric 
cancer is hypothesized to involve gastrin mediated 
trophic stimulus of gastric mucosa, gastric atrophy, 
and alteration of gut microbiota and gastric mucosal 
immunology.58 64 68
In our analyses, we observed a graded relation 
between duration of exposure and the risk of mortality 
due to chronic conditions including circulatory system 
diseases, neoplasms, and genitourinary system 
diseases. Notably, there was no relation between the 
duration of exposure and the risk of death due to 
infectious and parasitic diseases, most likely due to the 
acuteness of the clinical condition where the relation 
might be idiosyncratic.69
Given the observational nature of this study, we 
carefully considered potential biases which could 
result in false relations and designed a multipronged 
causal inference analytic approach to emulate a target 
randomized trial that would answer the research 
question. We considered the following strategies: first, 
we employed a new user design to enhance balance in 
comparison groups based on pretreatment status, and 
an active comparator control to reduce the chance of 
confounding by indication. Second, to avoid capturing 
reverse causation and to ensure the temporal direction 
between exposure and diseases that lead to cause 
specific mortality, we removed all events which 
occurred within 180 days after first exposure. Third, 
we applied inverse probability of treatment weighting 
based on high dimensional propensity scores to create 
a pseudo cohort whose treatment assignment was 
independent of measured confounders.70 Fourth, to 
reduce the probability that an observed association 
between PPIs and causes of death is contributed 
by unmeasured confounding, we employed an 
instrumental variable method.71 Results from two 
negative controls which showed no association 
between PPI use and transportation mortality, and no 
association between PPI use and death due to peptic 
ulcer disease, lessen concerns about unmeasured 
confounding and other biases. In particular, results 
from our negative control analysis of death due to 
peptic ulcer disease are consistent with those of 
multiple randomized controlled trials.43 Furthermore, 
the finding that PPI use was not associated with excess 
mortality due to digestive system diseases further lends 
validity to our approach. Taken together, the findings 
suggest that subjecting our approach to the scrutinous 
application of negative controls yielded results 
consistent with a priori expectations and results from 
randomized controlled trials, suggesting no observable 
biases in analyses of established relations.
Strengths and limitations of study
The study has several limitations. The cohort included 
US veterans who were mostly older, white, and 
male, which might limit the generalizability of the 
study results to a broader population. Although our 
application of several inclusion and exclusion criteria 
could have introduced selection bias, these criteria are 
needed for more accurate cohort definition (and new 
user definition) which will optimize the successful 
emulation of a target trial. In our analyses, we defined 
drug exposure based on Department of Veterans 
Affairs prescription records and by days of supply 
which might not necessarily be equivalent with days 
of use since patients can obtain PPIs through over-the-
counter purchase, by other means, or may not adhere 
Table 7 | Subcauses of death associated with taking proton pump inhibitors (PPIs) in patients without indication for acid 
suppression drugs at baseline (n=116 377)
Cause of death Subcause of death
Event rate per 100 (95% CI) Excess burden per 
1000 (95% CI)
Hazard ratio (95%CI)
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to a Department of Veterans Affairs prescription. 
Although we applied high dimensional propensity 
scores, and used instrumental variable methods, our 
overall approach is inherently limited by the validity 
of the underlying assumptions.40 Furthermore, while 
we used an active comparator design, and developed 
strategies to reduce confounding, channeling bias, 
and other forms of residual confounding might not be 
completely eliminated.72 To obtain sufficient follow-
up, we built a cohort of new users in 2003; as PPI 
use became more prevalent over the last decade, we 
anticipate that the proportion of patients where the risk 
of taking PPIs might outweigh potential benefit could 
have increased over time and as such our results could 
have underestimated the true burden of cause specific 
mortality. The study has several strengths, including 
the use of national large scale data from a network 
of integrated health systems, which were captured 
during routine medical care that minimizes selection 
bias. We employed a new user design with an active 
comparator control from a time when H2 blockers were 
commonly used, applied instrumental variable and 
high dimensional propensity score method, and tested 
positive and negative controls to more accurately 
estimate the burden of cause specific mortality.
Conclusions
The results show a consistent excess of cause specific 
mortality even among patients without documented 
gastrointestinal indications for acid suppression 
drugs—an alarming finding which might help guide the 
design and implementation of deprescription programs 
to reduce the number of unnecessary or un-indicated 
PPI prescriptions. The evidence that mortality due to 
cardiovascular disease, chronic kidney disease, and 
upper gastrointestinal cancer was not modified by the 
presence of baseline cardiovascular disease, chronic 
kidney disease, or upper gastrointestinal cancer, 
respectively, suggests the need for heightened vigilance 
among those with and—with equal importance—
those at risk of these conditions. The evidence from 
all available studies suggests that long term PPI use is 
associated with serious adverse events, including an 
increased risk of all cause mortality, and our results 
specifically suggest an increased mortality due to 
cardiovascular disease, chronic kidney disease, and 
upper gastrointestinal cancer. Because of the high 
prevalence of PPI use, the findings have public health 
implications and underscore the important message 
that PPIs should be used only when medically indicated 
and for the minimum duration necessary.
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